Susan00 personal page - To The Moon

Susan00

Susan00

No personal profile

2Follow

2Followers

0Topic

0Badge

2021-09-23

Ok

BOE Opens The Door for 2021 Rate Hike as Inflation Seen Above 4%

2021-09-18

Ok

Sorry, the original content has been removed

2021-09-11

Ok

Sorry, the original content has been removed

2021-09-12

Ok

Sorry, the original content has been removed

2021-05-06

Comment

The Bill And Melinda Gates Divorce: $130B And More Is At Stake

2021-09-22

Ok

Sorry, the original content has been removed

2021-09-07

Ok

Sorry, the original content has been removed

2021-09-07

Ok

Sorry, the original content has been removed

2021-09-20

Ok

The One Indicator That Has Wall Street Biting Its Nails

2021-09-16

Ok

Procept BioRobotics spikes 40% on its first day of trading

2021-09-14

Ok

Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO

2021-05-06

Comment

Shares of China vaccine makers slump on U.S. waiver support

2021-05-06

Comment

Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3579914987797156","uuid":"3579914987797156","gmtCreate":1616820963783,"gmtModify":1631016818175,"name":"Susan00","pinyin":"susan00","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":2,"tweetSize":29,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.83%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":863494591,"gmtCreate":1632410273513,"gmtModify":1676530776879,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863494591","repostId":"1162776746","repostType":4,"repost":{"id":"1162776746","kind":"news","pubTimestamp":1632407985,"share":"https://ttm.financial/m/news/1162776746?lang=en_US&edition=fundamental","pubTime":"2021-09-23 22:39","market":"uk","language":"en","title":"BOE Opens The Door for 2021 Rate Hike as Inflation Seen Above 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162776746","media":"Bloomberg","summary":"Ramsden switches to join Saunders in push to end bond buying.\n‘Considerable uncertainties remain’ in","content":"<div>\n<p>Ramsden switches to join Saunders in push to end bond buying.\n‘Considerable uncertainties remain’ in U.K. outlook, BOE says.\n\nThe Bank of England raised the prospect of hiking interest rates as soon ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-23/boe-sees-more-of-a-case-for-tightening-as-ramsden-switches-vote?srnd=markets-vp\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOE Opens The Door for 2021 Rate Hike as Inflation Seen Above 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOE Opens The Door for 2021 Rate Hike as Inflation Seen Above 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-23 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-09-23/boe-sees-more-of-a-case-for-tightening-as-ramsden-switches-vote?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ramsden switches to join Saunders in push to end bond buying.\n‘Considerable uncertainties remain’ in U.K. outlook, BOE says.\n\nThe Bank of England raised the prospect of hiking interest rates as soon ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-23/boe-sees-more-of-a-case-for-tightening-as-ramsden-switches-vote?srnd=markets-vp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-09-23/boe-sees-more-of-a-case-for-tightening-as-ramsden-switches-vote?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162776746","content_text":"Ramsden switches to join Saunders in push to end bond buying.\n‘Considerable uncertainties remain’ in U.K. outlook, BOE says.\n\nThe Bank of England raised the prospect of hiking interest rates as soon as November to contain a surge in inflation, which it now expects will exceed 4% following a spike in energy prices.\nNoting the “modest tightening” in policy foreseen over its forecast horizon in August, “some developments during the intervening period appear to have strengthened that case, although considerable uncertainties remain,” the Monetary Policy Committee said in a statement on Thursday.\nThe central bank also agreed that any future tightening should start with an interest-rate increase, even if that “became appropriate” before its bond-buying program finishes around the end of the year. Two of the nine MPC members pushed to end those purchases early, with Dave Ramsden making his first dissenting vote in in four years on the panel.\n“This appears to open the door to a rate rise by the end of this year, even while the BOE is injecting net stimulus into the economy via” quantitative easing, said Liz Martins, a senior economist at HSBC Holdings Plc in London. “The MPC does not want to rule out swift tightening if inflationary pressures intensify further.”\nThe next MPC meeting is set for Nov. 4.\nThe pound rallied and government bonds fell as investors reacted to a decision that puts the BOE in the more hawkish camp of advanced-world central banks in a pivotal week. On Wednesday, the U.S. Federal Reserve announced that officials may taper bond buying soon, and Norway raised its interest rate on Thursday.\nThe U.K. central bank is trying to tame inflation that accelerated well beyond its forecasts over the summer, reaching 3.2% last month. Its new focus is enabled by stronger-than-expected jobs data that show unemployment will peak well below worst-case scenarios predicted at the onset of the pandemic.\nWhile the BOE targets inflation of 2%, officials said the rate may temporarily exceed 4% in the final three months of the year. That’s slightly more than predicted in August.\nSpiking gas costs that have caused turmoil in U.K. energy markets “could represent a significant upside risk,” and also mean that consumer-price increases double the target until the second quarter of 2022, the MPC added.\nAllan Monks, an economist atJPMorgan Chase & Co., said the tone of the statement was more “hawkish than expected,” with policy makers attaching little weight to recent disappointing growth data.\nSignaling it could raise rates even before bond purchases expire the committee also appears to be “creating space to potentially hike as soon as November or December, something which we have previously attached a low probability to,” he said.\n\n “We still expect the labor market and a softer growth outlook to stay the BOE’s hand for longer than financial markets expect. But it now looks like a first hike will come in May, six months earlier than we forecast prior to the decision.”\n\n\n -- Dan Hanson, senior U.K. economist. Clickherefor full REACT.\n\nTraders now are pricing a 15-basis-point rate increase in February, compared with May previously. The pound rallied as much as 0.7%, while 10-year gilt yields rose by the most in a week.\nThe BOE kept its own benchmark unchanged at a record-low 0.1%, while its stock of asset purchases is set to total 895 billion pounds ($1.2 trillion) by the end of this year in line with expectations. Deputy Governor Ramsden joined Michael Saunders in pushing to end bond purchases as soon as possible.\n“There was increasing evidence from a range of global and domestic cost and price indicators that inflationary pressures were likely to persist,” the minutes said. “These members judged that, with the existing policy stance, inflation was likely to remain above the 2% target in the medium term.”\nThe decision was also notable for the participation of the MPC’s two newest members, who both voted with the majority on this occassion. Huw Pill, a formerGoldman Sachs Group Inc.analyst, replaced Andy Haldane as chief economist, and Catherine Mann, a one-time chief economist of the OECD, took up a post vacated by Gertjan Vlieghe.\nWhile the BOE’s more hawkish rhetoric follows a noticeable spike in inflation, it also comes against the backdrop of an economic recovery that has shown signs of losing steam amid supply bottlenecks and labor shortages.\nData released on Thursday showed the U.K. had about 5.8% of its workforce on furlough at the start of this month even though that support program is set to expire Sept. 30. September is also shaping up to be the weakest month for private-sector activity since the height of the winter lockdown,IHS Markitsaid on Thursday.\n“Based on the macro numbers, I don’t understand how the U.K. can justify being first for a hike,” said Fabrice Montagne, an economist atBarclays Plc.“The U.S. and Europe are ahead in terms of recovery. We might get a hike but it will be a very painful hike to deliver.”","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2009,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869833268,"gmtCreate":1632271211254,"gmtModify":1676530739250,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869833268","repostId":"2169637141","repostType":4,"isVote":1,"tweetType":1,"viewCount":2724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860065579,"gmtCreate":1632108770691,"gmtModify":1676530702810,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860065579","repostId":"1196172424","repostType":4,"repost":{"id":"1196172424","kind":"news","pubTimestamp":1632105381,"share":"https://ttm.financial/m/news/1196172424?lang=en_US&edition=fundamental","pubTime":"2021-09-20 10:36","market":"us","language":"en","title":"The One Indicator That Has Wall Street Biting Its Nails","url":"https://stock-news.laohu8.com/highlight/detail?id=1196172424","media":"Barrons","summary":"The stock market dropped because there’s something scarier than taxes, tapers, and contagion.","content":"<p>Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.</p>\n<p>The predictions of impending doom from Wall Street’s talking heads continued this past week. The reasons for a pullback are many: The stock market has rallied for too long and has gone up too smoothly, the Federal Reserve is about to remove the bond buying that has helped prop markets up, taxes are ready to rise, economic data are slowing. None of it really left a mark.</p>\n<p>But then the&nbsp;S&amp;P 500&nbsp;dropped 0.6%, to 4432.99, over the week, while the&nbsp;Dow Jones Industrial Average&nbsp;fell 0.1%, to 34,584.88, and the&nbsp;Nasdaq Composite&nbsp;slumped 0.5%, to 15,043.97. For the S&amp;P 500, it was the first close since June 18 below its 50-day moving average—a technical measure of the previous 50 days’ closes that often ends up acting as support or resistance and that currently sits at 4436.35. For traders, it was very frightening.</p>\n<p>That the drop also occurred on options expiration day—when options bets expire and are rolled over, typically a volatile day—also makes the moment fraught. Since May, options expiration has been the time for the S&amp;P 500 to make a quick test of its 50-day moving average before a bounce higher. And when I say quick, I mean quick, as it usually took the index a day, maybe two, to rebound.</p>\n<p>“The 50-Day MA discussion has been pounded into our heads with every drawdown,” writes Frank Cappelleri, desk strategist at Instinet. “And while we may be sick of hearing about it, the dip buying around the line has been a real phenomenon.”</p>\n<p>This time has a different feel to it. The S&amp;P 500’s sojourn near the 50-day has been longer, notes Jonathan Krinsky, chief market technician at Bay Crest Partners. It’s been sitting near it for about six trading days now, without a big drop or big bounce. “The current set-up looks a bit more like a consolidation on the 50 DMA, as opposed to the prior quick ‘V-shaped’ dips,” Krinsky writes. “What we are saying is that the current way in which we got here feels a bit different than the last four to five times.”</p>\n<p>Still, Krinsky acknowledges that one close below the 50-day isn’t enough to panic. That’s because the S&amp;P 500 has now gone 218 days without two closes below the average, the second-longest streak since 1990. We won’t know if that streak breaks until the end of trading on Monday.</p>\n<p>The market has plenty of excuses to break the 50-day, if it’s so inclined. Maybe Evergrande (ticker: 3333.Hong Kong), the troubled Chinese property developer, will prove to be a Lehman moment and bring the world’s markets down with it. Maybe the Fed will surprise everyone and start tapering this coming week. Maybe something is lurking out there like the Baba Yaga of the old fairy tales, and maybe it looks a lot like Keanu Reeves.</p>\n<p>But perhaps all the September weakness and worry are a good thing, setting the market up for its next run. “The ACWI is oversold again, and sentiment is not too optimistic,” writes Ned Davis Research’s Tim Hayes, commenting on the MSCI All-Country World Index. “The market’s resilience in the face of the negative September seasonality could be the preview of a bullish response to seasonal tendencies that turn favorable in the fourth quarter.”</p>\n<p>We just have to get there first.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The One Indicator That Has Wall Street Biting Its Nails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe One Indicator That Has Wall Street Biting Its Nails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.\nThe predictions of impending doom from Wall Street’s talking heads continued this past ...</p>\n\n<a href=\"https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196172424","content_text":"Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.\nThe predictions of impending doom from Wall Street’s talking heads continued this past week. The reasons for a pullback are many: The stock market has rallied for too long and has gone up too smoothly, the Federal Reserve is about to remove the bond buying that has helped prop markets up, taxes are ready to rise, economic data are slowing. None of it really left a mark.\nBut then the S&P 500 dropped 0.6%, to 4432.99, over the week, while the Dow Jones Industrial Average fell 0.1%, to 34,584.88, and the Nasdaq Composite slumped 0.5%, to 15,043.97. For the S&P 500, it was the first close since June 18 below its 50-day moving average—a technical measure of the previous 50 days’ closes that often ends up acting as support or resistance and that currently sits at 4436.35. For traders, it was very frightening.\nThat the drop also occurred on options expiration day—when options bets expire and are rolled over, typically a volatile day—also makes the moment fraught. Since May, options expiration has been the time for the S&P 500 to make a quick test of its 50-day moving average before a bounce higher. And when I say quick, I mean quick, as it usually took the index a day, maybe two, to rebound.\n“The 50-Day MA discussion has been pounded into our heads with every drawdown,” writes Frank Cappelleri, desk strategist at Instinet. “And while we may be sick of hearing about it, the dip buying around the line has been a real phenomenon.”\nThis time has a different feel to it. The S&P 500’s sojourn near the 50-day has been longer, notes Jonathan Krinsky, chief market technician at Bay Crest Partners. It’s been sitting near it for about six trading days now, without a big drop or big bounce. “The current set-up looks a bit more like a consolidation on the 50 DMA, as opposed to the prior quick ‘V-shaped’ dips,” Krinsky writes. “What we are saying is that the current way in which we got here feels a bit different than the last four to five times.”\nStill, Krinsky acknowledges that one close below the 50-day isn’t enough to panic. That’s because the S&P 500 has now gone 218 days without two closes below the average, the second-longest streak since 1990. We won’t know if that streak breaks until the end of trading on Monday.\nThe market has plenty of excuses to break the 50-day, if it’s so inclined. Maybe Evergrande (ticker: 3333.Hong Kong), the troubled Chinese property developer, will prove to be a Lehman moment and bring the world’s markets down with it. Maybe the Fed will surprise everyone and start tapering this coming week. Maybe something is lurking out there like the Baba Yaga of the old fairy tales, and maybe it looks a lot like Keanu Reeves.\nBut perhaps all the September weakness and worry are a good thing, setting the market up for its next run. “The ACWI is oversold again, and sentiment is not too optimistic,” writes Ned Davis Research’s Tim Hayes, commenting on the MSCI All-Country World Index. “The market’s resilience in the face of the negative September seasonality could be the preview of a bullish response to seasonal tendencies that turn favorable in the fourth quarter.”\nWe just have to get there first.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":1759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887095717,"gmtCreate":1631940454639,"gmtModify":1676530675125,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887095717","repostId":"2168574191","repostType":4,"isVote":1,"tweetType":1,"viewCount":3126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885047801,"gmtCreate":1631748514103,"gmtModify":1676530622767,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885047801","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://ttm.financial/m/news/2167559884?lang=en_US&edition=fundamental","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1,"symbols_score_info":{"PRCT":0.9}},"isVote":1,"tweetType":1,"viewCount":1871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886623643,"gmtCreate":1631587216582,"gmtModify":1676530583181,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886623643","repostId":"2167352505","repostType":4,"repost":{"id":"2167352505","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631580300,"share":"https://ttm.financial/m/news/2167352505?lang=en_US&edition=fundamental","pubTime":"2021-09-14 08:45","market":"us","language":"en","title":"Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2167352505","media":"Reuters","summary":"TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots ","content":"<p>TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.</p>\n<p>Takeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.</p>\n<p>But vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.</p>\n<p>Vaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.</p>\n<p>\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.</p>\n<p>Takeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.</p>\n<p>The company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.</p>\n<p>Japan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.</p>\n<p>About 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.</p>\n<p>Weber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.</p>\n<p>With some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.</p>\n<p>\"We don't rely on <a href=\"https://laohu8.com/S/AONE.U\">one</a> product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-14 08:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.</p>\n<p>Takeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.</p>\n<p>But vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.</p>\n<p>Vaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.</p>\n<p>\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.</p>\n<p>Takeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.</p>\n<p>The company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.</p>\n<p>Japan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.</p>\n<p>About 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.</p>\n<p>Weber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.</p>\n<p>With some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.</p>\n<p>\"We don't rely on <a href=\"https://laohu8.com/S/AONE.U\">one</a> product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","TAK":"武田制药","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167352505","content_text":"TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.\nTakeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.\nBut vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.\nVaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.\n\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.\nTakeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.\nThe company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.\nJapan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.\nAbout 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.\nWeber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.\nWith some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.\n\"We don't rely on one product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.","news_type":1,"symbols_score_info":{"MRNA":0.9,"TAK":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2428,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888035192,"gmtCreate":1631412487716,"gmtModify":1676530542958,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/888035192","repostId":"1127699574","repostType":4,"isVote":1,"tweetType":1,"viewCount":3022,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881860971,"gmtCreate":1631324095293,"gmtModify":1676530528328,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/881860971","repostId":"1105074635","repostType":4,"isVote":1,"tweetType":1,"viewCount":2710,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880302673,"gmtCreate":1631016775592,"gmtModify":1676530442898,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880302673","repostId":"2165335391","repostType":4,"isVote":1,"tweetType":1,"viewCount":2364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880302139,"gmtCreate":1631016751621,"gmtModify":1676530442890,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880302139","repostId":"2165335391","repostType":4,"isVote":1,"tweetType":1,"viewCount":2156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105890368,"gmtCreate":1620285601054,"gmtModify":1704341341405,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105890368","repostId":"1186255556","repostType":4,"repost":{"id":"1186255556","kind":"news","pubTimestamp":1620284285,"share":"https://ttm.financial/m/news/1186255556?lang=en_US&edition=fundamental","pubTime":"2021-05-06 14:58","market":"hk","language":"en","title":"Shares of China vaccine makers slump on U.S. waiver support","url":"https://stock-news.laohu8.com/highlight/detail?id=1186255556","media":"Reuters","summary":"SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. Presiden","content":"<p>SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines sent investors scrambling to reconsider high valuations.</p><p>The Shanghai shares of CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, tumbled as much as 16.91%. The company’s Hong Kong shares fell even further, at one point diving nearly 22%.</p><p>Shares of Shanghai Fosun Pharmaceutical Group fell by the 10% daily limit, as the CSI300 healthcare sub-index dropped more than 5%.</p><p>On Wednesday, Biden indicated his support for a waiver amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.</p><p>Any decision by the World Trade Organization on waivers for COVID-19 vaccines requires a consensus of all 164 members.</p><p>Worsening outbreaks have boosted demand for vaccine stocks in China’s retail-driven equity market.</p><p>“The patent waiver will definitely have some impact on China’s domestic COVID-19 vaccine makers, as it would increase the global vaccine supply,” said Hu Yunlong, a Beijing-based fund manager.</p><p>“The fall in Chinese vaccine makers is also partly due to a technical correction following their recent sharp gains.”</p><p>China’s healthcare sub-index jumped nearly 11% last month, adding froth to the already-high valuations in the sector. Data from China Securities Index Co showed the price-to-earnings ratio for the healthcare sector at above 62, as of April 30, compared with around 21 for the Shanghai and Shenzhen stock exchanges overall.</p><p>“Chinese vaccine stocks had been spurred recently by news of worsening situations in other countries, such as India,” said Wu Tianhao, an analyst at Western Securities.</p><p>While the patent waiver could hurt exports of Chinese vaccines, the overall impact on the sector would be limited.</p><p>“Domestic sales are still their main source of revenue,” Wu said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shares of China vaccine makers slump on U.S. waiver support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShares of China vaccine makers slump on U.S. waiver support\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 14:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines ...</p>\n\n<a href=\"https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186255556","content_text":"SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines sent investors scrambling to reconsider high valuations.The Shanghai shares of CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, tumbled as much as 16.91%. The company’s Hong Kong shares fell even further, at one point diving nearly 22%.Shares of Shanghai Fosun Pharmaceutical Group fell by the 10% daily limit, as the CSI300 healthcare sub-index dropped more than 5%.On Wednesday, Biden indicated his support for a waiver amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.Any decision by the World Trade Organization on waivers for COVID-19 vaccines requires a consensus of all 164 members.Worsening outbreaks have boosted demand for vaccine stocks in China’s retail-driven equity market.“The patent waiver will definitely have some impact on China’s domestic COVID-19 vaccine makers, as it would increase the global vaccine supply,” said Hu Yunlong, a Beijing-based fund manager.“The fall in Chinese vaccine makers is also partly due to a technical correction following their recent sharp gains.”China’s healthcare sub-index jumped nearly 11% last month, adding froth to the already-high valuations in the sector. Data from China Securities Index Co showed the price-to-earnings ratio for the healthcare sector at above 62, as of April 30, compared with around 21 for the Shanghai and Shenzhen stock exchanges overall.“Chinese vaccine stocks had been spurred recently by news of worsening situations in other countries, such as India,” said Wu Tianhao, an analyst at Western Securities.While the patent waiver could hurt exports of Chinese vaccines, the overall impact on the sector would be limited.“Domestic sales are still their main source of revenue,” Wu said.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":748,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105890014,"gmtCreate":1620285585438,"gmtModify":1704341341078,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/105890014","repostId":"1148620968","repostType":4,"repost":{"id":"1148620968","kind":"news","pubTimestamp":1620271207,"share":"https://ttm.financial/m/news/1148620968?lang=en_US&edition=fundamental","pubTime":"2021-05-06 11:20","market":"us","language":"en","title":"The Bill And Melinda Gates Divorce: $130B And More Is At Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1148620968","media":"Benzinga","summary":"When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.For those curious about how the other 1% live, here is ","content":"<div>\n<p>When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates...</p>\n\n<a href=\"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bill And Melinda Gates Divorce: $130B And More Is At Stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bill And Melinda Gates Divorce: $130B And More Is At Stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates...</p>\n\n<a href=\"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148620968","content_text":"When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.For those curious about how the other 1% live, here is a scorecard on the Gates’ wealth and what will be required when the time comes to divide their holdings after 27 years together.Rules Of Disengagement:One minor surprise arising from the news of the divorce was the absence of a prenuptial agreement, meaning there are no set boundaries to divide his from hers in this case.Also complicating matters is state law: The couple live in Washington, which is a community property state. That means a judge could potentially divide their marital assets equally,  which would mean Melinda could walk away with half of Bill’s $130-billion fortune.One consideration that will not be part of the divorce proceedings is child support: Melinda stated it's unneeded, as their children are over the age of 18.he Gates Property Empire:Earlier this year, an investigation byThe Land Reportuncovered a rather surprising fact about Bill Gates: he is the single largest owner of U.S. farmland, with a portfolio of more than 268,000 acres spread over more than a dozen states. Because this property was acquired after the couple married, this will be considered part of the assets to be divided.A separate report byWealth-Xfound Gates was the owner of a non-agricultural real estate portfolio worth more than $166 million. This portfolio includes the couple’s 66,000-square-foot lakeside home in Medina, Washington, which carries an estimated value of $65 million, along with a 30-acre estate in Wellington, Florida, a pair of luxury homes in California, a condo at Yellowstone Club in Big Sky, Montana and a private island in Belize.Investment Assets:Of course, no home is complete without tasteful furnishings, and Wealth-X pointed out that Gates has amassed an art collection valued at $130 million that includes the works of Andrew Wyeth and Winslow Homer.Gates also has a notebook from Leonardo Da Vinci that he acquired for $30.8 million in a 1994 auction, as well as four rare first-edition copies of F. Scott Fitzgerald's \"The Great Gatsby.\"Wealth-X has also catalogued Gates’ $650,000 sports car collection, which includes three flashy vehicles fromPorsche SEPOAHY 1.9%— a 1988 Porsche 959 Coupe, a Porsche 911 and a Porsche Carrera Cabriolet 964 — plus a Jaguar XJ6 and Ferrari 348.But Gates’ most considerable asset would be his $29.9 billion in holdings in Cascade Investment, which covers nearly one-quarter of his total wealth.Wealth-X determined Gates’ shareholdings through this company include an estimated $11.9 billion inJohn DeereDE 0.21%, $11 billion inCanadian National RailwayCNI 1.09%and $1.6 billion inDiageo plc DEO 0.2%.And while he is no longer running Microsoft, Gates still owns roughly $26.1 billion in shares.As for the Bill & Melinda Gates Foundation, the couple stated they would continue to work together on this philanthropic organization — and they transferred $20 billion of Microsoft stock into the foundation before announcing their divorce.Bill will be represented in the divorce by the law firm Munger Tolles & Olson, which was co-founded by Charlie Munger, vice chairman ofBerkshire Hathaway(NYSE:BRK-A) (NYSE:BRK-B), while Melinda will have attorney representation from the New York City law firm Paul, Weiss, Rifkind, Wharton & Garrison LLP.","news_type":1,"symbols_score_info":{"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105807828,"gmtCreate":1620285542864,"gmtModify":1704341340106,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3579914987797156","authorIdStr":"3579914987797156"},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105807828","repostId":"1197402336","repostType":4,"repost":{"id":"1197402336","kind":"news","pubTimestamp":1620273156,"share":"https://ttm.financial/m/news/1197402336?lang=en_US&edition=fundamental","pubTime":"2021-05-06 11:52","market":"us","language":"en","title":"Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'","url":"https://stock-news.laohu8.com/highlight/detail?id=1197402336","media":"Benzinga","summary":"Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitco","content":"<div>\n<p>Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 11:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197402336","content_text":"Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What Happened:ETC has soared 160.83% in a seven-day trailing period, while BTC and ETH have risen 3.54% and 26.80% in a similar period, according to CoinMarketCap data.At press time on Wednesday night, ETC traded 16.85% higher at $90.06 in a 24-hour period. BTC was up 4.46% at $57,201.19 and ETH was higher by 3.71% at $3,484.ETC is trading 10.43% below the all-time high of $100.03 it reached on Wednesday.Ethereum Classiccame into existenceafter a hard fork of the Ethereum blockchain took place in 2016 due to prevailing disagreements at the time in the community.Barry Silbert — CEO of Digital Currency Group, which owns Grayscale — is a well-known proponent of ETC.On Wednesday, Ethereum Classic noted that theGrayscale Ethereum Classic Trust(OTC:ETCG) has over $1 billion in assets under management.ETCG closed 27.76% higher at $67.15 on Wednesday.Why It Matters:ETC has caught the attention of the social media investment crowd. The cryptocurrency’s ticker featured in the Stocktwits list of top 10 trending streams at press time.The rise in ETC is despite the fact that it is not typically classified as an “Ethereum Killer,” which is thecase with several coinssuch asPolkadot(DOT),Solana(SOL), andCardano(ADA).Synergia Capital’s head of research, Denis Vinokourov, said that the rise in ETC “appears to be dominated by ‘cheaper’ Ethereum play and retail flow that has pushed DOGE to sky-high levels,” CoinDeskreported, dubbing the surge in ETC as a sign of froth in the cryptocurrency market.ETC’s retail fueled rise is similar to the story ofDogecoin(DOGE), which has soared 13,604.64% since the year began. However, even DOGE’s weekly gains of 102.68% are weaker than those of ETC. DOGE traded 6.63% higher at $0.63 at press time.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":790,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":863494591,"gmtCreate":1632410273513,"gmtModify":1676530776879,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863494591","repostId":"1162776746","repostType":4,"repost":{"id":"1162776746","kind":"news","pubTimestamp":1632407985,"share":"https://ttm.financial/m/news/1162776746?lang=en_US&edition=fundamental","pubTime":"2021-09-23 22:39","market":"uk","language":"en","title":"BOE Opens The Door for 2021 Rate Hike as Inflation Seen Above 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162776746","media":"Bloomberg","summary":"Ramsden switches to join Saunders in push to end bond buying.\n‘Considerable uncertainties remain’ in","content":"<div>\n<p>Ramsden switches to join Saunders in push to end bond buying.\n‘Considerable uncertainties remain’ in U.K. outlook, BOE says.\n\nThe Bank of England raised the prospect of hiking interest rates as soon ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-23/boe-sees-more-of-a-case-for-tightening-as-ramsden-switches-vote?srnd=markets-vp\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOE Opens The Door for 2021 Rate Hike as Inflation Seen Above 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOE Opens The Door for 2021 Rate Hike as Inflation Seen Above 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-23 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-09-23/boe-sees-more-of-a-case-for-tightening-as-ramsden-switches-vote?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ramsden switches to join Saunders in push to end bond buying.\n‘Considerable uncertainties remain’ in U.K. outlook, BOE says.\n\nThe Bank of England raised the prospect of hiking interest rates as soon ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-23/boe-sees-more-of-a-case-for-tightening-as-ramsden-switches-vote?srnd=markets-vp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-09-23/boe-sees-more-of-a-case-for-tightening-as-ramsden-switches-vote?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162776746","content_text":"Ramsden switches to join Saunders in push to end bond buying.\n‘Considerable uncertainties remain’ in U.K. outlook, BOE says.\n\nThe Bank of England raised the prospect of hiking interest rates as soon as November to contain a surge in inflation, which it now expects will exceed 4% following a spike in energy prices.\nNoting the “modest tightening” in policy foreseen over its forecast horizon in August, “some developments during the intervening period appear to have strengthened that case, although considerable uncertainties remain,” the Monetary Policy Committee said in a statement on Thursday.\nThe central bank also agreed that any future tightening should start with an interest-rate increase, even if that “became appropriate” before its bond-buying program finishes around the end of the year. Two of the nine MPC members pushed to end those purchases early, with Dave Ramsden making his first dissenting vote in in four years on the panel.\n“This appears to open the door to a rate rise by the end of this year, even while the BOE is injecting net stimulus into the economy via” quantitative easing, said Liz Martins, a senior economist at HSBC Holdings Plc in London. “The MPC does not want to rule out swift tightening if inflationary pressures intensify further.”\nThe next MPC meeting is set for Nov. 4.\nThe pound rallied and government bonds fell as investors reacted to a decision that puts the BOE in the more hawkish camp of advanced-world central banks in a pivotal week. On Wednesday, the U.S. Federal Reserve announced that officials may taper bond buying soon, and Norway raised its interest rate on Thursday.\nThe U.K. central bank is trying to tame inflation that accelerated well beyond its forecasts over the summer, reaching 3.2% last month. Its new focus is enabled by stronger-than-expected jobs data that show unemployment will peak well below worst-case scenarios predicted at the onset of the pandemic.\nWhile the BOE targets inflation of 2%, officials said the rate may temporarily exceed 4% in the final three months of the year. That’s slightly more than predicted in August.\nSpiking gas costs that have caused turmoil in U.K. energy markets “could represent a significant upside risk,” and also mean that consumer-price increases double the target until the second quarter of 2022, the MPC added.\nAllan Monks, an economist atJPMorgan Chase & Co., said the tone of the statement was more “hawkish than expected,” with policy makers attaching little weight to recent disappointing growth data.\nSignaling it could raise rates even before bond purchases expire the committee also appears to be “creating space to potentially hike as soon as November or December, something which we have previously attached a low probability to,” he said.\n\n “We still expect the labor market and a softer growth outlook to stay the BOE’s hand for longer than financial markets expect. But it now looks like a first hike will come in May, six months earlier than we forecast prior to the decision.”\n\n\n -- Dan Hanson, senior U.K. economist. Clickherefor full REACT.\n\nTraders now are pricing a 15-basis-point rate increase in February, compared with May previously. The pound rallied as much as 0.7%, while 10-year gilt yields rose by the most in a week.\nThe BOE kept its own benchmark unchanged at a record-low 0.1%, while its stock of asset purchases is set to total 895 billion pounds ($1.2 trillion) by the end of this year in line with expectations. Deputy Governor Ramsden joined Michael Saunders in pushing to end bond purchases as soon as possible.\n“There was increasing evidence from a range of global and domestic cost and price indicators that inflationary pressures were likely to persist,” the minutes said. “These members judged that, with the existing policy stance, inflation was likely to remain above the 2% target in the medium term.”\nThe decision was also notable for the participation of the MPC’s two newest members, who both voted with the majority on this occassion. Huw Pill, a formerGoldman Sachs Group Inc.analyst, replaced Andy Haldane as chief economist, and Catherine Mann, a one-time chief economist of the OECD, took up a post vacated by Gertjan Vlieghe.\nWhile the BOE’s more hawkish rhetoric follows a noticeable spike in inflation, it also comes against the backdrop of an economic recovery that has shown signs of losing steam amid supply bottlenecks and labor shortages.\nData released on Thursday showed the U.K. had about 5.8% of its workforce on furlough at the start of this month even though that support program is set to expire Sept. 30. September is also shaping up to be the weakest month for private-sector activity since the height of the winter lockdown,IHS Markitsaid on Thursday.\n“Based on the macro numbers, I don’t understand how the U.K. can justify being first for a hike,” said Fabrice Montagne, an economist atBarclays Plc.“The U.S. and Europe are ahead in terms of recovery. We might get a hike but it will be a very painful hike to deliver.”","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2009,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887095717,"gmtCreate":1631940454639,"gmtModify":1676530675125,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/887095717","repostId":"2168574191","repostType":4,"isVote":1,"tweetType":1,"viewCount":3126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":881860971,"gmtCreate":1631324095293,"gmtModify":1676530528328,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/881860971","repostId":"1105074635","repostType":4,"isVote":1,"tweetType":1,"viewCount":2710,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888035192,"gmtCreate":1631412487716,"gmtModify":1676530542958,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/888035192","repostId":"1127699574","repostType":4,"isVote":1,"tweetType":1,"viewCount":3022,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105890014,"gmtCreate":1620285585438,"gmtModify":1704341341078,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/105890014","repostId":"1148620968","repostType":4,"repost":{"id":"1148620968","kind":"news","pubTimestamp":1620271207,"share":"https://ttm.financial/m/news/1148620968?lang=en_US&edition=fundamental","pubTime":"2021-05-06 11:20","market":"us","language":"en","title":"The Bill And Melinda Gates Divorce: $130B And More Is At Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1148620968","media":"Benzinga","summary":"When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.For those curious about how the other 1% live, here is ","content":"<div>\n<p>When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates...</p>\n\n<a href=\"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bill And Melinda Gates Divorce: $130B And More Is At Stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bill And Melinda Gates Divorce: $130B And More Is At Stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates...</p>\n\n<a href=\"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"source_url":"https://www.benzinga.com/news/21/05/20967443/the-bill-and-melinda-gates-divorce-130b-and-more-is-at-stake","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148620968","content_text":"When MicrosoftMSFT 0.53%co-founder and ex-CEO Bill Gates announced the end of his marriage to Melinda Gates, he requested “space and privacy for our family as we begin to navigate this new life.”Gates’ request that people not pry into his world might be a tad difficult, given the pair are among the world’s richest married couples. Nor will it be easy for them to start a new life when their old one encompassed a complex financial environment.For those curious about how the other 1% live, here is a scorecard on the Gates’ wealth and what will be required when the time comes to divide their holdings after 27 years together.Rules Of Disengagement:One minor surprise arising from the news of the divorce was the absence of a prenuptial agreement, meaning there are no set boundaries to divide his from hers in this case.Also complicating matters is state law: The couple live in Washington, which is a community property state. That means a judge could potentially divide their marital assets equally,  which would mean Melinda could walk away with half of Bill’s $130-billion fortune.One consideration that will not be part of the divorce proceedings is child support: Melinda stated it's unneeded, as their children are over the age of 18.he Gates Property Empire:Earlier this year, an investigation byThe Land Reportuncovered a rather surprising fact about Bill Gates: he is the single largest owner of U.S. farmland, with a portfolio of more than 268,000 acres spread over more than a dozen states. Because this property was acquired after the couple married, this will be considered part of the assets to be divided.A separate report byWealth-Xfound Gates was the owner of a non-agricultural real estate portfolio worth more than $166 million. This portfolio includes the couple’s 66,000-square-foot lakeside home in Medina, Washington, which carries an estimated value of $65 million, along with a 30-acre estate in Wellington, Florida, a pair of luxury homes in California, a condo at Yellowstone Club in Big Sky, Montana and a private island in Belize.Investment Assets:Of course, no home is complete without tasteful furnishings, and Wealth-X pointed out that Gates has amassed an art collection valued at $130 million that includes the works of Andrew Wyeth and Winslow Homer.Gates also has a notebook from Leonardo Da Vinci that he acquired for $30.8 million in a 1994 auction, as well as four rare first-edition copies of F. Scott Fitzgerald's \"The Great Gatsby.\"Wealth-X has also catalogued Gates’ $650,000 sports car collection, which includes three flashy vehicles fromPorsche SEPOAHY 1.9%— a 1988 Porsche 959 Coupe, a Porsche 911 and a Porsche Carrera Cabriolet 964 — plus a Jaguar XJ6 and Ferrari 348.But Gates’ most considerable asset would be his $29.9 billion in holdings in Cascade Investment, which covers nearly one-quarter of his total wealth.Wealth-X determined Gates’ shareholdings through this company include an estimated $11.9 billion inJohn DeereDE 0.21%, $11 billion inCanadian National RailwayCNI 1.09%and $1.6 billion inDiageo plc DEO 0.2%.And while he is no longer running Microsoft, Gates still owns roughly $26.1 billion in shares.As for the Bill & Melinda Gates Foundation, the couple stated they would continue to work together on this philanthropic organization — and they transferred $20 billion of Microsoft stock into the foundation before announcing their divorce.Bill will be represented in the divorce by the law firm Munger Tolles & Olson, which was co-founded by Charlie Munger, vice chairman ofBerkshire Hathaway(NYSE:BRK-A) (NYSE:BRK-B), while Melinda will have attorney representation from the New York City law firm Paul, Weiss, Rifkind, Wharton & Garrison LLP.","news_type":1,"symbols_score_info":{"MSFT":0.9}},"isVote":1,"tweetType":1,"viewCount":543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869833268,"gmtCreate":1632271211254,"gmtModify":1676530739250,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869833268","repostId":"2169637141","repostType":4,"isVote":1,"tweetType":1,"viewCount":2724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880302139,"gmtCreate":1631016751621,"gmtModify":1676530442890,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880302139","repostId":"2165335391","repostType":4,"isVote":1,"tweetType":1,"viewCount":2156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880302673,"gmtCreate":1631016775592,"gmtModify":1676530442898,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/880302673","repostId":"2165335391","repostType":4,"isVote":1,"tweetType":1,"viewCount":2364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860065579,"gmtCreate":1632108770691,"gmtModify":1676530702810,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860065579","repostId":"1196172424","repostType":4,"repost":{"id":"1196172424","kind":"news","pubTimestamp":1632105381,"share":"https://ttm.financial/m/news/1196172424?lang=en_US&edition=fundamental","pubTime":"2021-09-20 10:36","market":"us","language":"en","title":"The One Indicator That Has Wall Street Biting Its Nails","url":"https://stock-news.laohu8.com/highlight/detail?id=1196172424","media":"Barrons","summary":"The stock market dropped because there’s something scarier than taxes, tapers, and contagion.","content":"<p>Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.</p>\n<p>The predictions of impending doom from Wall Street’s talking heads continued this past week. The reasons for a pullback are many: The stock market has rallied for too long and has gone up too smoothly, the Federal Reserve is about to remove the bond buying that has helped prop markets up, taxes are ready to rise, economic data are slowing. None of it really left a mark.</p>\n<p>But then the&nbsp;S&amp;P 500&nbsp;dropped 0.6%, to 4432.99, over the week, while the&nbsp;Dow Jones Industrial Average&nbsp;fell 0.1%, to 34,584.88, and the&nbsp;Nasdaq Composite&nbsp;slumped 0.5%, to 15,043.97. For the S&amp;P 500, it was the first close since June 18 below its 50-day moving average—a technical measure of the previous 50 days’ closes that often ends up acting as support or resistance and that currently sits at 4436.35. For traders, it was very frightening.</p>\n<p>That the drop also occurred on options expiration day—when options bets expire and are rolled over, typically a volatile day—also makes the moment fraught. Since May, options expiration has been the time for the S&amp;P 500 to make a quick test of its 50-day moving average before a bounce higher. And when I say quick, I mean quick, as it usually took the index a day, maybe two, to rebound.</p>\n<p>“The 50-Day MA discussion has been pounded into our heads with every drawdown,” writes Frank Cappelleri, desk strategist at Instinet. “And while we may be sick of hearing about it, the dip buying around the line has been a real phenomenon.”</p>\n<p>This time has a different feel to it. The S&amp;P 500’s sojourn near the 50-day has been longer, notes Jonathan Krinsky, chief market technician at Bay Crest Partners. It’s been sitting near it for about six trading days now, without a big drop or big bounce. “The current set-up looks a bit more like a consolidation on the 50 DMA, as opposed to the prior quick ‘V-shaped’ dips,” Krinsky writes. “What we are saying is that the current way in which we got here feels a bit different than the last four to five times.”</p>\n<p>Still, Krinsky acknowledges that one close below the 50-day isn’t enough to panic. That’s because the S&amp;P 500 has now gone 218 days without two closes below the average, the second-longest streak since 1990. We won’t know if that streak breaks until the end of trading on Monday.</p>\n<p>The market has plenty of excuses to break the 50-day, if it’s so inclined. Maybe Evergrande (ticker: 3333.Hong Kong), the troubled Chinese property developer, will prove to be a Lehman moment and bring the world’s markets down with it. Maybe the Fed will surprise everyone and start tapering this coming week. Maybe something is lurking out there like the Baba Yaga of the old fairy tales, and maybe it looks a lot like Keanu Reeves.</p>\n<p>But perhaps all the September weakness and worry are a good thing, setting the market up for its next run. “The ACWI is oversold again, and sentiment is not too optimistic,” writes Ned Davis Research’s Tim Hayes, commenting on the MSCI All-Country World Index. “The market’s resilience in the face of the negative September seasonality could be the preview of a bullish response to seasonal tendencies that turn favorable in the fourth quarter.”</p>\n<p>We just have to get there first.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The One Indicator That Has Wall Street Biting Its Nails</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe One Indicator That Has Wall Street Biting Its Nails\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 10:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.\nThe predictions of impending doom from Wall Street’s talking heads continued this past ...</p>\n\n<a href=\"https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.barrons.com/articles/stock-market-falls-because-theres-something-scarier-than-taxes-tapers-and-contagion-51631925838?mod=hp_DAY_7","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196172424","content_text":"Wall Street has found something scarier than tapering,axes,and contagion. It’s called the 50-day moving average.\nThe predictions of impending doom from Wall Street’s talking heads continued this past week. The reasons for a pullback are many: The stock market has rallied for too long and has gone up too smoothly, the Federal Reserve is about to remove the bond buying that has helped prop markets up, taxes are ready to rise, economic data are slowing. None of it really left a mark.\nBut then the S&P 500 dropped 0.6%, to 4432.99, over the week, while the Dow Jones Industrial Average fell 0.1%, to 34,584.88, and the Nasdaq Composite slumped 0.5%, to 15,043.97. For the S&P 500, it was the first close since June 18 below its 50-day moving average—a technical measure of the previous 50 days’ closes that often ends up acting as support or resistance and that currently sits at 4436.35. For traders, it was very frightening.\nThat the drop also occurred on options expiration day—when options bets expire and are rolled over, typically a volatile day—also makes the moment fraught. Since May, options expiration has been the time for the S&P 500 to make a quick test of its 50-day moving average before a bounce higher. And when I say quick, I mean quick, as it usually took the index a day, maybe two, to rebound.\n“The 50-Day MA discussion has been pounded into our heads with every drawdown,” writes Frank Cappelleri, desk strategist at Instinet. “And while we may be sick of hearing about it, the dip buying around the line has been a real phenomenon.”\nThis time has a different feel to it. The S&P 500’s sojourn near the 50-day has been longer, notes Jonathan Krinsky, chief market technician at Bay Crest Partners. It’s been sitting near it for about six trading days now, without a big drop or big bounce. “The current set-up looks a bit more like a consolidation on the 50 DMA, as opposed to the prior quick ‘V-shaped’ dips,” Krinsky writes. “What we are saying is that the current way in which we got here feels a bit different than the last four to five times.”\nStill, Krinsky acknowledges that one close below the 50-day isn’t enough to panic. That’s because the S&P 500 has now gone 218 days without two closes below the average, the second-longest streak since 1990. We won’t know if that streak breaks until the end of trading on Monday.\nThe market has plenty of excuses to break the 50-day, if it’s so inclined. Maybe Evergrande (ticker: 3333.Hong Kong), the troubled Chinese property developer, will prove to be a Lehman moment and bring the world’s markets down with it. Maybe the Fed will surprise everyone and start tapering this coming week. Maybe something is lurking out there like the Baba Yaga of the old fairy tales, and maybe it looks a lot like Keanu Reeves.\nBut perhaps all the September weakness and worry are a good thing, setting the market up for its next run. “The ACWI is oversold again, and sentiment is not too optimistic,” writes Ned Davis Research’s Tim Hayes, commenting on the MSCI All-Country World Index. “The market’s resilience in the face of the negative September seasonality could be the preview of a bullish response to seasonal tendencies that turn favorable in the fourth quarter.”\nWe just have to get there first.","news_type":1,"symbols_score_info":{".SPX":0.9,".IXIC":0.9,".DJI":0.9}},"isVote":1,"tweetType":1,"viewCount":1759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885047801,"gmtCreate":1631748514103,"gmtModify":1676530622767,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885047801","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://ttm.financial/m/news/2167559884?lang=en_US&edition=fundamental","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1,"symbols_score_info":{"PRCT":0.9}},"isVote":1,"tweetType":1,"viewCount":1871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886623643,"gmtCreate":1631587216582,"gmtModify":1676530583181,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886623643","repostId":"2167352505","repostType":4,"repost":{"id":"2167352505","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631580300,"share":"https://ttm.financial/m/news/2167352505?lang=en_US&edition=fundamental","pubTime":"2021-09-14 08:45","market":"us","language":"en","title":"Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2167352505","media":"Reuters","summary":"TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots ","content":"<p>TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.</p>\n<p>Takeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.</p>\n<p>But vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.</p>\n<p>Vaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.</p>\n<p>\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.</p>\n<p>Takeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.</p>\n<p>The company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.</p>\n<p>Japan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.</p>\n<p>About 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.</p>\n<p>Weber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.</p>\n<p>With some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.</p>\n<p>\"We don't rely on <a href=\"https://laohu8.com/S/AONE.U\">one</a> product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-14 08:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.</p>\n<p>Takeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.</p>\n<p>But vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.</p>\n<p>Vaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.</p>\n<p>\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.</p>\n<p>Takeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.</p>\n<p>The company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.</p>\n<p>Japan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.</p>\n<p>About 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.</p>\n<p>Weber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.</p>\n<p>With some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.</p>\n<p>\"We don't rely on <a href=\"https://laohu8.com/S/AONE.U\">one</a> product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","TAK":"武田制药","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167352505","content_text":"TOKYO, Sept 14 (Reuters) - Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.\nTakeda, Japan's biggest drugmaker and among the top 10 globally after its 2019 takeover of Shire Plc, has traditionally been known more for its cancer and gastrointestinal treatments.\nBut vaccines have defined much of the company's activities during the coronavirus pandemic, as it worked to bring foreign-developed shots into Japan.\nVaccine production is a business that \"when established, has a very long life,\" Takeda CEO Christophe Weber said in an interview broadcast at Reuters Events' Pharma Japan 2021 conference on Tuesday.\n\"There is no generic of vaccines, for example. So it's a different type of lifecycle, but it can be a very good business if you bring innovation,\" he added.\nTakeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several South American and Asian countries this year. Takeda has been working for almost 10 years on the shot, which is now in the \"last stage,\" Weber said.\nThe company has imported some 50 million doses of Moderna's COVID-19 vaccine into Japan and has a license to manufacture Novavax Inc's vaccine, which is still undergoing trials.\nJapan's government has agreed to buy another 50 million Moderna shots, to be delivered next year, along with 150 million Novavax doses.\nAbout 1.6 million Moderna doses were recalled in Japan this month after the discovery of small metal contaminants in some vials, a problem traced back to a production line in Spain.\nWeber said such problems sometimes occur in pharma manufacturing, brushing off the suggestion it was caused by companies rushing to bring vaccines to market.\nWith some of its main sellers due to lose patent protection in the coming years, Takeda is betting heavily on a pipeline of more than 10 drugs in late-stage development. One of those, a blood cancer treatment known as Pevonedistat, fell out of the running this month after poor trial results.\n\"We don't rely on one product in our pipeline, or two, when we have 40 in clinical stage,\" Weber said.","news_type":1,"symbols_score_info":{"MRNA":0.9,"TAK":0.9,"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2428,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105890368,"gmtCreate":1620285601054,"gmtModify":1704341341405,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105890368","repostId":"1186255556","repostType":4,"repost":{"id":"1186255556","kind":"news","pubTimestamp":1620284285,"share":"https://ttm.financial/m/news/1186255556?lang=en_US&edition=fundamental","pubTime":"2021-05-06 14:58","market":"hk","language":"en","title":"Shares of China vaccine makers slump on U.S. waiver support","url":"https://stock-news.laohu8.com/highlight/detail?id=1186255556","media":"Reuters","summary":"SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. Presiden","content":"<p>SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines sent investors scrambling to reconsider high valuations.</p><p>The Shanghai shares of CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, tumbled as much as 16.91%. The company’s Hong Kong shares fell even further, at one point diving nearly 22%.</p><p>Shares of Shanghai Fosun Pharmaceutical Group fell by the 10% daily limit, as the CSI300 healthcare sub-index dropped more than 5%.</p><p>On Wednesday, Biden indicated his support for a waiver amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.</p><p>Any decision by the World Trade Organization on waivers for COVID-19 vaccines requires a consensus of all 164 members.</p><p>Worsening outbreaks have boosted demand for vaccine stocks in China’s retail-driven equity market.</p><p>“The patent waiver will definitely have some impact on China’s domestic COVID-19 vaccine makers, as it would increase the global vaccine supply,” said Hu Yunlong, a Beijing-based fund manager.</p><p>“The fall in Chinese vaccine makers is also partly due to a technical correction following their recent sharp gains.”</p><p>China’s healthcare sub-index jumped nearly 11% last month, adding froth to the already-high valuations in the sector. Data from China Securities Index Co showed the price-to-earnings ratio for the healthcare sector at above 62, as of April 30, compared with around 21 for the Shanghai and Shenzhen stock exchanges overall.</p><p>“Chinese vaccine stocks had been spurred recently by news of worsening situations in other countries, such as India,” said Wu Tianhao, an analyst at Western Securities.</p><p>While the patent waiver could hurt exports of Chinese vaccines, the overall impact on the sector would be limited.</p><p>“Domestic sales are still their main source of revenue,” Wu said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shares of China vaccine makers slump on U.S. waiver support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShares of China vaccine makers slump on U.S. waiver support\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 14:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines ...</p>\n\n<a href=\"https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.reuters.com/article/health-coronavirus-china-stocks/shares-of-china-vaccine-makers-slump-on-u-s-waiver-support-idUSL1N2MT09E","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186255556","content_text":"SHANGHAI, May 6 (Reuters) - Shares in Chinese vaccine makers slumped on Thursday after U.S. President Joe Biden’s support for a proposed waiver of intellectual property rights on COVID-19 vaccines sent investors scrambling to reconsider high valuations.The Shanghai shares of CanSino Biologics Inc, a single-dose COVID-19 vaccine maker, tumbled as much as 16.91%. The company’s Hong Kong shares fell even further, at one point diving nearly 22%.Shares of Shanghai Fosun Pharmaceutical Group fell by the 10% daily limit, as the CSI300 healthcare sub-index dropped more than 5%.On Wednesday, Biden indicated his support for a waiver amid growing concern that big outbreaks in India could allow the rise of vaccine-resistant strains of the deadly virus, undermining a global recovery.Any decision by the World Trade Organization on waivers for COVID-19 vaccines requires a consensus of all 164 members.Worsening outbreaks have boosted demand for vaccine stocks in China’s retail-driven equity market.“The patent waiver will definitely have some impact on China’s domestic COVID-19 vaccine makers, as it would increase the global vaccine supply,” said Hu Yunlong, a Beijing-based fund manager.“The fall in Chinese vaccine makers is also partly due to a technical correction following their recent sharp gains.”China’s healthcare sub-index jumped nearly 11% last month, adding froth to the already-high valuations in the sector. Data from China Securities Index Co showed the price-to-earnings ratio for the healthcare sector at above 62, as of April 30, compared with around 21 for the Shanghai and Shenzhen stock exchanges overall.“Chinese vaccine stocks had been spurred recently by news of worsening situations in other countries, such as India,” said Wu Tianhao, an analyst at Western Securities.While the patent waiver could hurt exports of Chinese vaccines, the overall impact on the sector would be limited.“Domestic sales are still their main source of revenue,” Wu said.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":748,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105807828,"gmtCreate":1620285542864,"gmtModify":1704341340106,"author":{"id":"3579914987797156","authorId":"3579914987797156","name":"Susan00","avatar":"https://static.tigerbbs.com/e9593f92fe85142fbcb895d4e8cf421f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579914987797156","idStr":"3579914987797156"},"themes":[],"htmlText":"Comment&nbsp;","listText":"Comment&nbsp;","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/105807828","repostId":"1197402336","repostType":4,"repost":{"id":"1197402336","kind":"news","pubTimestamp":1620273156,"share":"https://ttm.financial/m/news/1197402336?lang=en_US&edition=fundamental","pubTime":"2021-05-06 11:52","market":"us","language":"en","title":"Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'","url":"https://stock-news.laohu8.com/highlight/detail?id=1197402336","media":"Benzinga","summary":"Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitco","content":"<div>\n<p>Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Ethereum Classic's Outpacing Of Bitcoin, Ethereum, Dogecoin Gains All About Being 'Cheaper?'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-06 11:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What ...</p>\n\n<a href=\"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/markets/cannabis/21/05/20980403/is-ethereum-classics-outpacing-of-bitcoin-ethereum-dogecoin-gains-all-about-being-cheaper","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197402336","content_text":"Gains in Ethereum Classic(ETC) continue to outpace the ones made by the cryptocurrency’s peers Bitcoin(BTC),Ethereum(ETH), andDogecoin(DOGE), which all enjoy larger market capitalizations.What Happened:ETC has soared 160.83% in a seven-day trailing period, while BTC and ETH have risen 3.54% and 26.80% in a similar period, according to CoinMarketCap data.At press time on Wednesday night, ETC traded 16.85% higher at $90.06 in a 24-hour period. BTC was up 4.46% at $57,201.19 and ETH was higher by 3.71% at $3,484.ETC is trading 10.43% below the all-time high of $100.03 it reached on Wednesday.Ethereum Classiccame into existenceafter a hard fork of the Ethereum blockchain took place in 2016 due to prevailing disagreements at the time in the community.Barry Silbert — CEO of Digital Currency Group, which owns Grayscale — is a well-known proponent of ETC.On Wednesday, Ethereum Classic noted that theGrayscale Ethereum Classic Trust(OTC:ETCG) has over $1 billion in assets under management.ETCG closed 27.76% higher at $67.15 on Wednesday.Why It Matters:ETC has caught the attention of the social media investment crowd. The cryptocurrency’s ticker featured in the Stocktwits list of top 10 trending streams at press time.The rise in ETC is despite the fact that it is not typically classified as an “Ethereum Killer,” which is thecase with several coinssuch asPolkadot(DOT),Solana(SOL), andCardano(ADA).Synergia Capital’s head of research, Denis Vinokourov, said that the rise in ETC “appears to be dominated by ‘cheaper’ Ethereum play and retail flow that has pushed DOGE to sky-high levels,” CoinDeskreported, dubbing the surge in ETC as a sign of froth in the cryptocurrency market.ETC’s retail fueled rise is similar to the story ofDogecoin(DOGE), which has soared 13,604.64% since the year began. However, even DOGE’s weekly gains of 102.68% are weaker than those of ETC. DOGE traded 6.63% higher at $0.63 at press time.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":790,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}